Genentech CEO Alexander Hardy on Tuesday urged healthcare leaders to reform the 340B program together in the wake of the recent New York Times exposé about a Virginia health system’s alleged misuse of the 340B program.
“As leaders in healthcare, we need to do better to ensure patients have access to affordable healthcare,” Hardy said in an Oct. 4 LinkedIn post. “340B is an important program that was created with the well-intentioned goal of serving some of our nation’s most vulnerable patients. It is time to come together to take a critical look at where the program stands today and enact the necessary policy reforms to protect patients and ensure the long-term viability of the program.”
Genentech CEO Alexander Hardy on Tuesday urged healthcare leaders to reform the 340B program together in the wake of the recent New York Times exposé about a Virginia health system’s alleged misuse of the 340B program.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
